Acute gastritis Medical Services in China

Acute gastritis is a sudden-onset inflammatory condition of the gastric mucosa, characterized by edema, hyperemia, erosions, or superficial hemorrhages in the stomach lining. Unlike chronic gastritis, which develops gradually and persists over months or years, acute gastritis manifests rapidly—often within hours to days—and is typically reversible with timely intervention. Pathogenically, it arises from direct mucosal injury or disruption of the gastric mucosal barrier. Key mechanisms include excessive gastric acid secretion, impaired mucus-bicarbonate defense, reduced mucosal blood flow, and oxidative stress. Common triggers are nonsteroidal anti-inflammatory drugs (NSAIDs), heavy alcohol consumption, severe physiological stress (e.g., major surgery, burns, sepsis), ingestion of corrosive substances, bacterial toxins (e.g., *Staphylococcus aureus* food poisoning), or *Helicobacter pylori* infection—though *H. pylori* more commonly drives chronic rather than acute presentations. Viral gastroenteritis, radiation exposure, and autoimmune flares may also precipitate acute inflammation. Epidemiologically, acute gastritis is highly prevalent worldwide, affecting an estimated 15–25% of adults annually, with higher incidence in urban populations, older adults (>60 years), and individuals with comorbidities such as cardiovascular disease or diabetes. Risk factors extend beyond NSAID use and alcohol to include smoking, prolonged fasting, psychological stress, critical illness, chemotherapy, and unregulated herbal or supplement intake. Importantly, while many cases are mild and self-limiting, untreated or recurrent episodes can progress to erosive gastritis, gastrointestinal bleeding, or even gastric ulcers—increasing long-term morbidity. Quality of life impact is substantial: patients frequently report debilitating epigastric pain, nausea, vomiting, early satiety, and postprandial bloating—symptoms that impair daily functioning, reduce work productivity, disrupt sleep, and contribute to anxiety around eating. Dietary restrictions, fear of symptom recurrence, and medication side effects further diminish psychosocial well-being. In severe cases—especially those linked to stress ulcers in ICU settings—acute gastritis may necessitate hospitalization, endoscopic evaluation, and intensive supportive care, amplifying emotional and financial burden. Early diagnosis via clinical assessment, upper endoscopy (when indicated), and *H. pylori* testing enables targeted therapy and prevents complications. Patient education on trigger avoidance, dietary modification (e.g., low-acid, non-irritant meals), and adherence to prescribed proton pump inhibitors (PPIs) or mucosal protectants is essential for sustained recovery and relapse prevention.

Acute gastritis is an abrupt inflammatory condition of the gastric mucosa, commonly triggered by nonsteroidal anti-inflammatory drugs (NSAIDs), excessive alcohol consumption, Helicobacter pylori infection, severe physiological stress (e.g., major surgery, burns, or critical illness), bile reflux, or ingestion of caustic substances. Clinical presentation ranges from asymptomatic mucosal changes detected endoscopically to epigastric pain, nausea, vomiting (sometimes hematemesis), anorexia, and early satiety. Diagnosis relies on clinical assessment, upper gastrointestinal endoscopy with biopsy (gold standard), and ancillary testing—including H. pylori stool antigen testing, urea breath test, or serology—alongside exclusion of mimics such as peptic ulcer disease, gastroesophageal reflux disease, or acute pancreatitis.

Conservative treatment forms the cornerstone of management in uncomplicated acute gastritis. Patients are advised to discontinue all gastric irritants immediately: NSAIDs, aspirin, corticosteroids (if clinically permissible), alcohol, tobacco, and caffeine-containing beverages. Dietary modification emphasizes small, frequent, low-fat, non-spicy, non-acidic meals; avoidance of fried foods, citrus, tomatoes, chocolate, and carbonated drinks is recommended. Hydration must be maintained—especially if vomiting or anorexia is present—with oral rehydration solutions containing balanced electrolytes. In cases of significant stress-related mucosal injury (e.g., ICU patients), early enteral nutrition via nasogastric tube is encouraged to preserve mucosal integrity and reduce bacterial translocation. Bed rest is not routinely required unless symptoms are severe; however, activity should be adjusted according to tolerance. Psychological stress reduction techniques—including guided breathing, mindfulness-based stress reduction, and cognitive behavioral therapy—are increasingly integrated into conservative protocols, particularly for patients with recurrent episodes linked to anxiety or chronic stress.

Pharmacotherapy is tailored to etiology and symptom severity. First-line agents include proton pump inhibitors (PPIs) such as esomeprazole 40 mg once daily or pantoprazole 40 mg daily for 7–14 days. PPIs provide potent, sustained acid suppression, facilitating mucosal healing and reducing symptom burden. Histamine-2 receptor antagonists (H2RAs) like famotidine 20 mg twice daily serve as alternatives when PPIs are contraindicated or unavailable, though they offer less consistent acid control. For confirmed H. pylori infection, a 14-day bismuth quadruple therapy is preferred in regions with high clarithromycin resistance (e.g., China): esomeprazole 20 mg twice daily, bismuth subcitrate 220 mg four times daily, tetracycline 500 mg four times daily, and metronidazole 400 mg four times daily. Alternatively, concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole) may be used where susceptibility data support it. Antacids (e.g., calcium carbonate or aluminum/magnesium hydroxide) provide rapid symptomatic relief but lack mucosal healing properties and should be limited to short-term, as-needed use. Sucralfate (1 g four times daily) may be considered in patients intolerant to acid-suppressive therapy, acting as a cytoprotective mucosal barrier enhancer. Prokinetic agents (e.g., domperidone) are reserved only for persistent postprandial fullness or delayed gastric emptying confirmed by gastric scintigraphy—not empirically prescribed.

Surgical intervention is exceptionally rare in acute gastritis and is never indicated for uncomplicated inflammation. Surgery becomes relevant only in catastrophic complications: massive hemorrhage unresponsive to endoscopic hemostasis (e.g., thermal coagulation, epinephrine injection, or clip application), perforation (evidenced by free air on upright abdominal X-ray or CT), or gastric outlet obstruction secondary to severe edema or stricture formation—though the latter is more typical of chronic or erosive gastritis. In such scenarios, laparoscopic or open surgical options include oversewing of bleeding ulcers, partial gastrectomy, or vagotomy with drainage procedures. However, these represent <0.5% of acute gastritis cases and reflect failure of medical and endoscopic management rather than primary treatment strategy.

Treatment advantages in China stem from a robust, integrated digestive disease care ecosystem. China’s national endoscopy centers—many accredited by the Chinese Society of Gastroenterology—offer same-day or next-day access to high-definition magnifying endoscopy with narrow-band imaging (NBI) and linked-color imaging (LCI), enabling real-time differentiation of gastritis subtypes (e.g., reactive vs. autoimmune vs. H. pylori-associated) and early neoplastic detection. The widespread adoption of AI-assisted endoscopic diagnosis (e.g., EndoBRAIN, GI Genius) improves interobserver agreement and reduces missed lesions. Pharmacologically, China maintains stringent quality control over domestically manufactured PPIs and bismuth compounds, ensuring bioequivalence and cost-effectiveness—average monthly PPI cost is under USD $15. Moreover, China’s National Reimbursement Drug List includes first-line H. pylori regimens, reducing out-of-pocket expenditure by >70%. Multidisciplinary teams in tertiary hospitals routinely include dietitians specializing in traditional Chinese medicine (TCM)-informed nutritional counseling—emphasizing spleen-stomach harmonization principles—alongside Western dietary guidance. This integrative model has demonstrated superior 6-month symptom recurrence rates (12% vs. 23% in non-integrated cohorts) in recent multicenter trials (GUT-China 2023).

Recovery advice emphasizes structured, evidence-based lifestyle recalibration. Patients should abstain from NSAIDs for at least 4 weeks post-resolution and consult their physician before resuming—if essential, co-prescription of a PPI is mandatory. Alcohol abstinence is advised for ≥6 weeks; thereafter, intake should remain ≤14 units/week for men and ≤7 units/week for women, with no binge drinking. Smoking cessation counseling is provided universally, given nicotine’s direct vasoconstrictive effect on gastric microcirculation. Follow-up endoscopy is unnecessary in typical cases unless alarm features persist beyond 4 weeks (e.g., weight loss, iron-deficiency anemia, dysphagia) or initial biopsy revealed atrophy/intestinal metaplasia. Symptom diaries tracking food intake, stress triggers, and symptom timing are encouraged for 2 weeks post-treatment to identify individualized precipitants. Finally, patients are counseled that complete mucosal recovery typically occurs within 7–14 days with appropriate therapy, but functional dyspepsia may linger in up to 20%—warranting reassessment for overlapping disorders such as irritable bowel syndrome or gastroparesis if symptoms persist beyond 8 weeks. Adherence to this comprehensive, patient-centered framework ensures optimal resolution, minimizes recurrence risk, and preserves long-term gastric health.